Ser198
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser198  -  CDC25C (human)

Site Information
sDELMEFsLKDQEAK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448636

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 4 ) , immunoprecipitation ( 4 ) , mass spectrometry ( 1 ) , mutation of modification site ( 4 ) , phospho-antibody ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PLK1 (human) ( 4 )
Kinases, in vitro:
PLK1 (human) ( 2 , 4 ) , PLK3 (human) ( 2 , 3 )
Phosphatases, in vitro:
PPP1CA (human) ( 4 )
Treatments:
nocodazole ( 4 ) , thymidine ( 4 )

Downstream Regulation
Effects of modification on CDC25C:
intracellular localization ( 4 )

References 

1

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

2

Iida M, Matsuda M, Komatani H (2008) Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1. Biochem J 411, 27-32
18062778   Curated Info

3

Bahassi el M, Hennigan RF, Myer DL, Stambrook PJ (2004) Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation. Oncogene 23, 2658-63
14968113   Curated Info

4

Toyoshima-Morimoto F, Taniguchi E, Nishida E (2002) Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 3, 341-8
11897663   Curated Info